Federal prisons must stock naloxone to prevent overdose deaths

What it does

This bill requires the Federal Bureau of Prisons to stock naloxone (an opioid overdose reversal drug) at every federal prison in multiple accessible locations—medical units, staff areas, visiting rooms, housing units, dining halls, and common areas. It mandates annual training for staff and incarcerated people on how to recognize and treat overdoses, requires documentation of every naloxone use, shields incarcerated people from liability if they administer it in good faith, and directs the BOP to report annually to Congress on compliance, overdose incidents, and expired supplies. The bill authorizes $6 million for 2026 and $2 million annually for 2027–2028.

Why we flagged it

The bill is a straightforward operational directive to a federal agency (BOP) to implement a specific public health intervention (naloxone availability and training) in federal prisons. It is not a tax measure, appropriation, or regulatory carve-out—it is a mandate backed by modest appropriations.

What the text implies

• Naloxone availability in prisons may reduce overdose-related deaths and emergency medical costs, but the bill does not address underlying opioid supply or addiction treatment capacity—it is a harm-reduction measure, not a cure.
• The liability shield for incarcerated people administering naloxone in good faith is protective but may create ambiguity about what constitutes 'good faith' in a prison setting, potentially leading to disputes over whether an administration was justified.
• Annual reporting to Congress on overdose incidents and naloxone use will create a public record of overdose prevalence in federal prisons, which may increase political pressure for broader addiction treatment and supply-reduction measures.
• The bill does not mandate naloxone availability in state or local jails, only federal facilities—leaving a significant gap in coverage for the majority of incarcerated people in the U.S. criminal justice system.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Incarcerated people and prison staff gain a life-saving tool and training to prevent overdose deaths—a direct public health benefit with no offsetting cost to citizens. The bill imposes no new restrictions on rights, no liability exposure, and no hidden subsidies; it is a straightforward mandate to equip federal prisons with a proven harm-reduction measure.

Who stands to gain

• pharmaceutical manufacturers of naloxone (Amphastar, Kaléo, Adapt Pharma/Purdue, others)
• medical suppliers and distributors of naloxone kits
• training and consulting firms contracted by BOP

Named in the bill

Bureau of Prisons (BOP), Federal Bureau of Prisons, U.S. Department of Justice, FDA (Federal Food and Drug Administration), Amphastar Pharmaceuticals, Kaléo, Adapt Pharma (Purdue Pharma subsidiary), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

4 cosponsors: 4 Democrats.

• Dec 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 17, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.